Ignite Creation Date:
2024-05-06 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 2:32 PM
Study NCT ID:
NCT05366153
Status:
RECRUITING
Last Update Posted:
2023-09-28
First Post:
2022-05-04
Brief Title:
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Sponsor:
Baker Heart and Diabetes Institute
Organization:
Baker Heart and Diabetes Institute
Study Overview
Official Title:
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer REDEEM-CAD
Status:
RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REDEEM-CAD
Brief Summary:
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy 5 years ago
Detailed Description:
REDEEM-CAD is a prospective multi-centre study in which a process of evaluating the risk of coronary artery disease is studied in cancer survivors 40-70 years with chemotherapy or radiotherapy 5 years ago The efficacy of this CAD risk evaluation will be compared with the broad community in two existing studies - CAUGHT-CAD and EDCAD This unique ScreeningManagement Plan SMP has 2 components 1 A novel clinical and imaging-based screening algorithm to select those most likely to develop coronary artery disease 2 A clinical review to ensure optimal risk factor control and cardio protection
Follow-up of treated patients will continue for an average of 36 months with clinic reviews at 12 24 and 36 months The results will define the prevalence of subclinical coronary artery disease and the feasibility and the efficacy of the SMP
Follow-up of treated patients will continue for an average of 36 months with clinic reviews at 12 24 and 36 months The results will define the prevalence of subclinical coronary artery disease and the feasibility and the efficacy of the SMP
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None